Description
Description: This assay employs a two-site sandwich ELISA to quantitate FAM57B in samples. An antibody specific for FAM57B has been pre-coated onto a microplate. Standards and samples are pipetted into the wells and any FAM57B present is bound by the immobilized antibody. After removing any unbound substances, a biotin-conjugated antibody specific for FAM57B is added to the wells. After washing, Streptavidin conjugated Horseradish Peroxidase (HRP) is added to the wells. Following a wash to remove any unbound avidin-enzyme reagent, a substrate solution is added to the wells and color develops in proportion to the amount of FAM57B bound in the initial step. The color development is stopped and the intensity of the color is measured.
Overview: FAM57B contains 1 TLC (TRAM/LAG1/CLN8) domain. The CT120B protein was predicted to have six transmembrane domains. The green fluorescent protein-tagged CT120B was localized on plasma membrane and in cytoplasm in SPC-A-1 cells. The expression of CT120B/A in normal lung tissue and in lung cancer cells was also examined. Results showed that the stable CT120B overexpression in SPC-A-1 cells resulted in a reduction of cell growth rate, and inhibited tumorigenecity and anchorage-independent growth in nude mice. The functions of CT120A and CT120B for cell growth appeared antagonistic. The delayed G1/S phase transition might contribute to the inhibitory activities of CT120B on cell growth and that the deleted 32 amino acids missing in CT120B might be essential for the oncogenetic activities of CT120A